Acelyrin CEO Mina Kim (L) and Alumis CEO Martin Babler
Less than two years after blockbuster IPO, Acelyrin merges with Alumis to combine cash, assets
After running into clinical hurdles with its “diamond in the rough” strategy, Los Angeles immunology biotech Acelyrin is handing over its last …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
